32461-83-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-N-isobutyl-acetamide is utilized as a key intermediate in the synthesis of various pharmaceutical products. Its unique chemical structure allows for the development of new drugs with potential therapeutic benefits.
Used in Organic Compounds Production:
As a building block, 2-Chloro-N-isobutyl-acetamide is employed in the production of other organic compounds, contributing to the advancement of chemical research and the creation of novel materials.
Safety Considerations:
Due to its chemical properties, it is essential to handle 2-Chloro-N-isobutyl-acetamide with care and adhere to proper safety protocols to ensure the well-being of individuals working with 2-Chloro-N-isobutyl-acetamide.

InChI:InChI=1/C6H12ClNO/c1-5(2)4-8-6(9)3-7/h5H,3-4H2,1-2H3,(H,8,9)

Upstream product

• 4960-82-1 dichlorodiacetamide 
• 78-81-9 isobutylamine 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 18498-20-9 2-N-iso-butyl-2-oxoethyl phosphonium chloride 
• 62872-62-2 diethyl {2-(isobutylamino)-2-oxoethyl}phosphonate 
• 76810-33-8 C₁₃H₁₈N₂O₂ 
• 163629-04-7 1-(i-butylaminocarbonylmethyl)-2-methyl-indole 
• 163629-05-8 1-(i-butylaminocarbonylmethyl)-2-phenyl-indole 
• 5161-25-1 O,O-Dimethyl-S-(N-isobutyl-carbamoylmethyl)-phosphorodithioat 

Relevant academic research and scientific papers

Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2

Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.

Carbamylmethyl Mercaptoacetate Thioether: A Novel Scaffold for the Development of L1 Metallo-β-lactamase Inhibitors

Given the clinical importance of metallo-β-lactamases (MβLs), a new scaffold, N-substituted carbamylmethyl mercaptoacetate thioether, was constructed. The obtained molecules 1-16 inhibited MβLs from all three subclasses, but preferentially L1 from subclass B3. Compound 9 with a p-carboxyphenyl substituent exhibited the broadest spectrum with at least 70% inhibition of enzymes from all subclasses at 100 μM, while compound 5 with a p-methylphenyl substituent was the most potent inhibitor of any individual enzyme, with 97% inhibition at 100 μM and an IC50 value of 0.41 μM against L1. Isothermal titration calorimetry assays corroborate findings from UV-vis spectrophotometric assays that the inhibition of L1 by 5 is dose-dependent. Docking studies suggest that the carboxyl group, the sulfide atom, and the carbonyl group of the carbamyl coordinate Zn2 in a chelating fashion. Using E. coli cells expressing L1, 6 and 8 were able to decrease cefazolin minimum inhibitory concentration 8-fold.

Quinazoline dione derivatives and preparation method and application thereof

The invention provides novel quinazoline dione derivatives and a preparation method and application thereof. The compounds include compounds with the structure shown in the general formula V in the description and pharmaceutically acceptable salts or hydrates thereof. The compounds are active ligands of novel cannabinoid II receptors (CB2) and can be used for preparing medicine for treating, preventing and relieving CB2 receptor-mediated diseases, wherein the medicine is an agonist or partial agonist or inverse agonist or antagonist of CB2 receptors.

TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS

Provided are methods of treating infectious diseases in mammals comprising administering a compound that inhibits glucose uptake. Particular infectious diseases that may be treated include malaria, leishmaniasis, African trypanosomiasis, tuberculosis, HIV, HCMV or herpes virus. In a first aspect, the invention features a method of treating infectious diseases in a mammal, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a compound or prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug, wherein the compound is an inhibitor of glucose uptake.

GLUCOSE UPTAKE INHIBITORS

Provided hererin are compounds that modulate glucose uptake activityand are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS

The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z and q are defined as set forth in the specification. The inve

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE

The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3 and Z are defined as set forth in the sp

Stereoselective synthesis of naturally occurring unsaturated amide alkaloids by a modified Ramberg-Baecklund reaction

A convenient and rapid approach for the synthesis of naturally occurring unsaturated amide alkaloids 1a-1n by the recently developed one-flask Ramberg-Baecklund reaction is described. The starting material was alcohol 3, which was transformed into thiolacetate 4 using the Mitsunobu reaction. In situ cleavage of acetyl moiety of 4, followed by alkylation of the resulting thiol with appropriate chloroacetamide 5, provided the sulfide 6. Oxidation of sulfide 6 gave the corresponding sulfone 2. Treatment of the sulfone 2 with the dibromodifluoromethane in the presence of alumina-supported potassium hydroxide in dichloromethane solution afforded unsaturated amide alkaloids 1a-1n. To the best of our knowledge, the synthesis of 1e and 1i was reported for the first time.

Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders

Compounds of formula (I), in which R, R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification. The invention also concerns the salts of said compounds, the preparation thereof and the drugs containing same.

Phenyl or bicyclo-alkenylfluoro amide pesticides

Compound of the formula (I): or a salt thereof, wherein Q1 is a phenyl ring or a fused bicyclic ring system containing 9 or 10 ring carbon atoms at least one ring being aromatic, or Q1 is a dihalovinyl group; Q is an alkyl chain containing 1 to 12 carbon atoms and optionally containing one or two oxygen atoms and/or an unsaturated group --CR7 =CR8 --, or --C=C--, wherein R7 and R8 are selected from hydrogen or halo; a is 0 or 1; b is 0 or 1; the sum of a and b is 0 or 1; R2, R3, R4, R5 and R6 are the same or different, and are independently selected from hydrogen, halo and C1-4 alkyl; R1 is selected from hydrogen and C1-6 hydrocarbyl optionally substituted by dioxalanyl, halo, cyano, trifluoromethyl, trifluoromethylthio or C1-6 alkoxy are disclosed which have pesticidal activity. Pesticidal formulations containing the compounds of the formula (I), their use in the control of pests and methods for their preparation are also disclosed.